[Sam Tiktin]

NAD+ (nicotinamide adenine dinucleotide) shows up constantly in longevity discussions, usually alongside precursor compounds like NMN and NR. This post separates the well-replicated findings from the parts of the story that are still genuinely open.

What NAD+ Is

NAD+ is a coenzyme present in every living cell, essential for converting nutrients into cellular energy (ATP) and for supporting the activity of enzymes involved in DNA repair and cellular signaling. It is not itself a peptide, but it’s closely tied to peptide and longevity research because cellular NAD+ levels decline with age, and that decline has been linked to reduced mitochondrial function and impaired cellular repair capacity.

What Published Research Explores

Because NAD+ itself doesn’t cross cell membranes well when taken orally, most human research has focused on precursor compounds — primarily nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — that the body converts into NAD+. A 2025 human trial published in Nature Metabolism directly compared NMN, NR, and nicotinamide (Nam) in 65 adults, finding that both NMN and NR roughly doubled circulating NAD+ levels after two weeks of daily supplementation, while nicotinamide did not produce the same effect. The same research proposed that gut bacteria play a role in converting NMN and NR into nicotinic acid, which in turn boosts circulating NAD+, and reported associated increases in short-chain fatty acids linked to gut barrier and inflammation outcomes.

Beyond the NAD+-raising effect itself, clinical trials are underway examining downstream outcomes: a randomized controlled trial examined nicotinamide riboside in long-COVID patients with persistent cognitive and physical symptoms, and separate trials are testing NAD+ precursors in heart failure and other age-related conditions.

What’s Still Unknown

Raising blood NAD+ levels is now a well-replicated finding, but whether that translates into meaningful functional improvements in the tissues most relevant to aging and disease remains actively debated and is not yet settled by the current trial evidence. Most completed human trials are short (weeks, not years), and long-term safety and efficacy data is limited.

Common Misunderstandings

“Raises NAD+ levels” and “slows aging” are not interchangeable claims — the first is well-supported for NMN and NR; the second is a hypothesis these trials are still testing. NAD+, NMN, and NR are also frequently conflated in casual discussion despite being chemically distinct (a coenzyme versus two different precursor molecules), which matters when comparing study results between them.

Related Reading

Browse Cellular Health & Longevity Research for related discussion, and see our MOTS-c Research Overview for another mitochondrially-linked compound. The NAD+ directory entry has additional reference material.

Questions for Discussion

Given that raising blood NAD+ is well-replicated but functional benefit is still unsettled, what outcome measures do you think future trials should prioritize? Do you think the gut-bacteria-mediated conversion pathway changes how NMN/NR research should be interpreted? Has anyone seen long-term (multi-year) human trial data on NAD+ precursors we should add here?

This post summarizes publicly available research literature for educational and discussion purposes. It is not medical advice.

References

• Direct comparison of NAD+ precursors (NMN, NR, and nicotinamide) in humans. Nature Metabolism. 2025.
• An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of NMN and NR. Food Frontiers. 2025. onlinelibrary.wiley.com
• Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine. thelancet.com

[Author]

Posts